KEYMED BIO-B (02162) has reached a licensing agreement for the registration and commercialization of siponimod injection in 18 countries and regions, including Southeast Asia and Central Asia.

KEYMED BIO-B (02162) announced that Kangnuo Pharma has signed an exclusive licensing agreement with multinational pharmaceutical company Aeira Pte. Ltd. (Aeira). The two parties will collaborate on the market registration and commercialization of Kangnuo's independently developed monoclonal antibody targeting IL-4RSipoqubai injection (trade name: Kangyueda) in Southeast Asia and Central Asia. According to the agreement, Kangnuo will receive an upfront payment, milestone payments for the approval of market applications in various countries, and commercialization milestone payments, as well as the right to receive royalties based on the net sales of the product in the licensed area, calculated at up to high double-digit rates. Aeira will be responsible for the registration and commercialization of Sipoqubai injection in 11 countries in Southeast Asia (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, Timor-Leste, Vietnam) as well as 5 countries in Central Asia (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan), along with the Hong Kong Special Administrative Region and the Macao Special Administrative Region, totaling 18 countries and regions. Kangnuo will continue to be responsible for the production and supply of Sipoqubai injection for Aeira. This collaboration marks an important milestone in Kangnuo's international strategy for innovative biopharmaceuticals. Leveraging the unique business network and registration experience of its partner in Southeast Asia and Central Asia, it aims to accelerate the market launch and commercialization process of Sipoqubai injection in these regions, further enhancing the global accessibility of the company's innovative products and benefiting more patients.